SLC5A2 and type 2 diabetes mellitus: Sodium‒glucose cotransporter 2 (SGLT2) inhibitors are a promising class of insulin-independent antihyperglycemic agents that have garnered significant attention in the treatment of T2D, especially in patients who are at risk for renal or cardiovascular complications [2, 4, 5].